Key Takeaways
- • The CFTC is citing CME Group's own trading data and executive statements in court filings to argue CME has not been harmed by the approval of Kalshi's Bitcoin perpetual futures contract (BTCPERP).
- • CME Bitcoin futures volume reached 298,958 contracts in August 2026, a 15.3% increase from May 2026, the month the CFTC approved Kalshi's product on May 29, 2026.
- • CFTC filings say CME executives stated on July 22, 2026 that no institutional client demand for perpetual contracts exists and that CME could launch its own perpetual product.
- • The central legal question is narrow: whether CME has standing to challenge the approval, which requires a concrete, imminent injury.
- • A ruling for the CFTC could signal that US regulation can accommodate perpetual contracts and open the door to similar approvals for other exchanges.
Summary
The Commodity Futures Trading Commission is using CME Group's own numbers in its legal defense against CME's challenge to the approval of Kalshi's Bitcoin perpetual futures contract. In court filings, the CFTC points to CME's trading data and statements from its executives to argue that the exchange has not been materially harmed by the new product, according to the publisher's reporting.
The CFTC approved Kalshi's BTCPERP contract on May 29, 2026, making it the first US-regulated Bitcoin perpetual futures product. CME Group filed suit on June 18, 2026, challenging both the product's classification as a futures contract and the process the agency used to approve it. CME argues the CFTC bypassed standard regulatory procedures and that the approval threatens competition in the futures market. The case is before Judge Colleen Kollar-Kotelly. The CFTC has moved to dismiss, and as of mid-October 2026 the court had not ruled. CME's response to the motion to dismiss was due October 2, 2026.
The immediate legal issue is standing rather than the merits of perpetual futures regulation. CME must show a concrete, imminent injury, and the CFTC contends the evidence does not support that. CME's Bitcoin futures volumes grew after the approval, reaching 298,958 contracts in August 2026, a 15.3% increase from May. According to CFTC court filings, CME executives said on July 22, 2026 that institutional clients had no demand for perpetual contracts and that CME could launch its own perpetual product if it chose. The CFTC combines these points to argue that CME's claimed harm is speculative or non-existent.
Perpetual futures already dominate global crypto derivatives, largely because offshore exchanges have offered them for years. Unlike standard futures, perpetual contracts have no expiration date and use a funding rate mechanism to keep prices near spot. US traders have largely been excluded from these products, so Kalshi's approval was an early opening. The classification question remains untested in court: perpetual contracts sit in a gray zone under the Commodity Exchange Act's definition of a futures contract. Even a ruling limited to standing could shape how regulators and courts approach that debate.
The CFTC approved Kalshi's BTCPERP contract on May 29, 2026, making it the first US-regulated Bitcoin perpetual futures product. CME Group filed suit on June 18, 2026, challenging both the product's classification as a futures contract and the process the agency used to approve it. CME argues the CFTC bypassed standard regulatory procedures and that the approval threatens competition in the futures market. The case is before Judge Colleen Kollar-Kotelly. The CFTC has moved to dismiss, and as of mid-October 2026 the court had not ruled. CME's response to the motion to dismiss was due October 2, 2026.
The immediate legal issue is standing rather than the merits of perpetual futures regulation. CME must show a concrete, imminent injury, and the CFTC contends the evidence does not support that. CME's Bitcoin futures volumes grew after the approval, reaching 298,958 contracts in August 2026, a 15.3% increase from May. According to CFTC court filings, CME executives said on July 22, 2026 that institutional clients had no demand for perpetual contracts and that CME could launch its own perpetual product if it chose. The CFTC combines these points to argue that CME's claimed harm is speculative or non-existent.
Perpetual futures already dominate global crypto derivatives, largely because offshore exchanges have offered them for years. Unlike standard futures, perpetual contracts have no expiration date and use a funding rate mechanism to keep prices near spot. US traders have largely been excluded from these products, so Kalshi's approval was an early opening. The classification question remains untested in court: perpetual contracts sit in a gray zone under the Commodity Exchange Act's definition of a futures contract. Even a ruling limited to standing could shape how regulators and courts approach that debate.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.